Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Bausch Health Companies Inc    BHC   CA0717341071

BAUSCH HEALTH COMPANIES INC (BHC)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Bausch Health : Up Over 12%, on Pace for Largest Percent Increase Since Nov 2017 -- Data Talk

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/12/2018 | 05:45pm CEST

Bausch Health Companies Inc. (BHC) is currently at $23.25, up $2.58 or 12.48%.

-- Would be highest close since Aug. 30, 2018, when it closed at $23.60

-- On pace for largest percent increase since Nov. 7, 2017, when it rose 17.11%

-- Earlier Wednesday, Bausch Health along with its wholly owned subsidiary, Salix Pharmaceuticals, said it has reached an agreement in a patent dispute over 550 mg tablets of Xifaxan

-- Up 11.89% year-to-date

-- Up 64.78% from 52 weeks ago (Sept. 13, 2017), when it closed at $14.11

-- Up 110.22% from its 52-week closing low of $11.06 on Nov. 2, 2017

-- Traded as high as $24.10; highest intraday level since Aug. 8, 2018, when it hit $24.30

-- Up 16.59% at today's intraday high; largest intraday percent increase since May 8, 2018, when it rose as much as 17.18%

All data as of 11:16:34 AM

Source: Dow Jones Market Data, FactSet

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAUSCH HEALTH COMPANIES IN
09/24BAUSCH HEALTH : Announces Participation In Upcoming Investor Conferences
PR
09/18TUESDAY 9/18 INSIDER BUYING REPORT : Bhc, ibtx
AQ
09/18TODAY'S RESEARCH REPORTS ON TRENDING : Bausch Health Companies and OPKO Health
AC
09/14BAUSCH HEALTH : Announces Resolution of XIFAXAN Intellectual Property Litigation
AQ
09/14GLAXOSMITHKLINE : Xenon further strengthens balance sheet with $63M follow-on
AQ
09/13BAUSCH HEALTH : + Lomb Announces Publication Of Pivotal Phase 3 Data On Lotepred..
AQ
09/13TODAY’S RESEARCH REPORTS ON STOCKS T : Bausch Health Companies and Vital Therapi..
AC
09/13BAUSCH HEALTH : Salix Announces U.S. Launch of PLENVU, the First and Only 1-Lite..
AQ
09/13BAUSCH HEALTH : Reduces Debt by Additional $107 Million, Eliminating All Remaini..
AQ
09/13BAUSCH HEALTH : Norgine and its partner salix announce the us launch of plenvu
AQ
More news
News from SeekingAlpha
09/25Pfizer facing difficult path to ramp up biosimilar business 
09/25INSIDER WEEKENDS : 3 Insiders Of The Company Formerly Known As Valeant Pharmaceu.. 
09/24Express Scripts taking credit for Gilead's planned launch of generic HCV meds 
09/19Almirall's tildrakizumab OK'd in Europe for plaque psoriasis 
09/18HYG AND U.S. HIGH-YIELD MARKET OUTLO : Week Ending September 16, 2018 
Financials ($)
Sales 2018 8 472 M
EBIT 2018 3 104 M
Net income 2018 -3 712 M
Debt 2018 23 890 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 3,84x
EV / Sales 2019 3,72x
Capitalization 8 660 M
Chart BAUSCH HEALTH COMPANIES INC
Duration : Period :
Bausch Health Companies Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUSCH HEALTH COMPANIES IN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 17,2 $
Spread / Average Target -30%
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive Vice President
Jerzy Janeczko Head-Information Technology
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BAUSCH HEALTH COMPANIES INC22.94%8 660
JOHNSON & JOHNSON2.26%376 847
PFIZER20.90%257 522
NOVARTIS-0.63%217 697
ROCHE HOLDING LTD.-5.48%209 212
MERCK AND COMPANY25.79%188 241